

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>	<b>01.02 - Policy</b>
<b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	<b>08.31.15 - Revised</b> <b>1997 - Author</b>

## **01.02 – Blood Borne Pathogens (BBP) - Occupational Post-Exposure Prophylaxis**

**Purpose**                    The purpose of this document is to establish UTMB policy for the initiation of prophylaxis after occupational exposure to the human immunodeficiency virus (HIV) and hepatitis B virus (HBV) and early treatment of infection with the hepatitis C virus (at time of seroconversion) to prevent chronic infection. This policy has been developed from the most current medical literature, clinical experience at UTMB, the September, 2013 recommendations from the US Public Health Service Guideline (1) and the CDC December 20, 2013 document on prevention of Hepatitis B infection in Health-Care Personnel (2). This prophylaxis protocol and regimen will be continuously updated with the most recent medical information.

**Audience**             All employees of UTMB hospitals, clinics, outpatient surgical center, contract workers, volunteers, and students.

- Definitions**
- Occupational exposures requiring the initiation of prophylaxis are defined as:
    - Percutaneous injury (e.g. needlestick, laceration with a sharp object)
    - Contact of mucous membranes or ocular membranes
    - Contact of non-intact skin (e.g. skin that is chapped, abraded)

with

Blood or other potentially infectious fluid (semen; vaginal secretions; and cerebrospinal, synovial, pleural, peritoneal, pericardial and amniotic fluids; bloody body fluids and unfixed tissue).
  
  - Occupational exposures requiring monitoring include the three above requiring prophylaxis and:
    - Contact with intact skin that is prolonged or involves an extensive area

with

Blood or other potentially infectious fluid (semen; vaginal secretions; and cerebrospinal, synovial, pleural, peritoneal, pericardial and amniotic fluids; bloody body fluids and unfixed tissue).

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>  <b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	<b>01.02 - Policy</b>  <b>08.31.15 - Revised</b> <b>1997 - Author</b>
---	--

Occupational Exposure Monitoring

All UTMB employees and students with a documented occupational exposure shall have the exposure evaluated and documented by a healthcare provider following the standard protocol.

- At the Employee Health/Student Health, the healthcare provider will recommend prophylaxis for percutaneous exposures, contact of mucous membranes or non-intact skin.  
with
- Blood or other potentially infectious fluid (semen; vaginal secretions; and cerebrospinal, synovial, pleural, peritoneal, pericardial and amniotic fluids; bloody body fluids and unfixed tissue).
- Healthcare providers in the Emergency Department or in outlying clinics will recommend initial prophylaxis and refer exposed persons to the Employee Health Center/Student Health Services at UTMB on the next business day for follow up.

Prophylaxis

Prophylaxis shall be recommended to all UTMB employees or students:

- HIV:
  - For percutaneous exposures, contact of mucous membranes or non-intact skin.  
with
  - Blood or other potentially infectious fluid (semen; vaginal secretions; and cerebrospinal, synovial, pleural, peritoneal, pericardial and amniotic fluids; bloody body fluids and unfixed tissue).
    - Ideally within two hours after exposures, but may be initiated up to 72 hours after exposure.
    - With appropriate drug therapy.
    - Until the source-patient blood has been obtained and analyzed. If the source-patient HIV status is determined to be negative, prophylaxis will be discontinued.
    - HBV-Prophylaxis for HBV prevention will be evaluated on an individual basis.
    - HCV-Employees/students testing positive for Hepatitis C Qualitative RNA (PCR) at 6 weeks, 3 months or 6 months, will be referred immediately to a hepatologist for early treatment to prevent chronic hepatitis C infection.

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>  <b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	<b>01.02 - Policy</b>  <b>08.31.15 - Revised</b> <b>1997 - Author</b>
---	--

## EMPLOYEE/STUDENT CHECKLIST

- Wash exposed area immediately.
- Notify Supervisor immediately (supervisor to assist with obtaining source consent & lab work).
  - Have supervisor document in source’s medical record “source of occupational exposure” and that labs were drawn for HIV, HCV, and HBsAg (Hepatitis B surface antigen) with source’s consent.

- Seek post-exposure care:

for employees on campus report to

for students on campus report to

Week Days  
Employee Health (7:30 AM-4:30 PM)  
(409) 747-9172

Week Days  
Student Health (8AM-5PM)  
(409) 747-9508

- Report to Emergency Department, after hours, weekends, or holidays (**Follow-up in Employee Health/Student Health the next business day**).

**Employee/student should report to Employee Health/Student Health or Emergency Department as soon as possible, but at least within 2 hours of exposure.**

- Off-site Exposures - Follow clinic specific policy.  
Obtain packet from supervisor or visit website (see below) ‡ for required forms, procedures, and information.
- Complete “Blood Borne Pathogen (BBP) Exposure Notification Form” [In packet & available at Employee Health].
  - Off-site – Complete form and fax to Employee Health/Student Health.
  - On-campus – Report to Employee Health/Student Health (form will be completed there).
  - If seen in the Emergency Department, form should be completed there and faxed
  - to Employee Health/Student Health.

Employee Health  
Fax (409) 747-9182

Student Health  
Fax (409) 747-9330

**\*\*\*You must report the exposure and have HIV lab testing done within ten (10) days to receive maximum benefits if a Worker’s Comp claim were to be filed in the future.**

- Follow up with Employee Health/Student Health.
- ‡For questions, visit: [www.utmb.edu/policy/hcepidem/search/01-02.pdf](http://www.utmb.edu/policy/hcepidem/search/01-02.pdf)

## SUPERVISOR/FACULTY CHECKLIST

- Refer employee/student for post exposure care immediately.

*for employees on campus report to*      *for students on campus report to*

**Employee Health**  
**(409) 747-9172**

**Student Health**  
**(409) 747-9508**

Employee/student should report to Emergency Department, after hours, weekends, or holidays (**Follow-up in Employee Health/Student Health the next business day**).

**Employee/student should report to Employee Health/Student Health or Emergency Department as soon as possible, but at least within 2 hours of exposure.**

- Assist employee/student with obtaining source consent and source lab work.
- Document in source's medical record "source of occupational exposure" and that labs were drawn for HIV, HCV, and HBsAg with source's consent.
- Remind employee/student to report exposure by completing "BBP Exposure Notification Form".

- Off-site – Complete form and fax to Employee Health/Student Health.

Employee Health  
Fax (409) 747-9182

Student Health  
Fax (409) 747-9330

- On-campus – Report to Employee Health/Student Health (form will be completed there).  
- If seen in the Emergency Department, form should be completed there and faxed to

Employee Health/Student Health.

Employee Health  
Fax (409) 747-9182

Student Health  
Fax (409) 747-9330

- For questions call Employee Health Center at (409)747-9172 or Student Health at (409)747-9508; after hours call the Access Center at 1-800-917-8906.

**For questions, visit [www.utmb.edu/policy/hcepidem/search/01-02.pdf](http://www.utmb.edu/policy/hcepidem/search/01-02.pdf)**

## PROVIDER CHECKLIST

- Provide necessary medical care to treat the injury/exposure.
  - Refer to the BBP Flow Chart and Procedures [Enclosed] as a guide for post-exposure care
- Use Laboratory testing forms [enclosed] as a reference.
- Use UTMB Occupational Exposure prescription to prescribe only enough medication until follow-up appointment or source results available.
- Complete the BBP Exposure Notification Form [enclosed] and fax to Employee Health/Student Health.
  - Employee Health – FAX # (409) 747-9182
  - Student Health – FAX # (409) 747-9330
- Provide patient education information [enclosed].
- Complete Informed Consent for Prophylaxis form [enclosed].
- Billing may be submitted to:
  - UTMB, Employee Health
  - c/o Director of Employee Health
  - 301 University Boulevard, Route 0159
  - Galveston, TX 77555-0159
- Billing instructions for Students' Off Campus Exposures
  - Student's Insurance should be billed
  - The balance after insurance is billed, should be brought to Student Health by the student or the student should contact Student Health at 409-747-9508.

***Reimbursement will be for reasonable & customary charges for authorized or medically necessary tests as noted in enclosed information. Any additional charges will not be reimbursed.***

## ***POST-EXPOSURE PROCEDURE***

- I. MANAGE THE EXPOSURE
  - A. Wash the area immediately with soap and water.
  - B. For exposure to eyes, mouth, and/or nose flush area with water.
  
- II. NOTIFY SUPERVISOR/FACULTY IMMEDIATELY
  - A. Supervisors will assist in obtaining source consent and lab work.
  - B. Supervisors & faculty shall release the employee or student from their duties immediately to seek post-exposure care.**
  
- III. PROCEDURE FOR SOURCE TESTING
  - A. Obtain source consent & lab specimen.
  - B. Use Physician Order Entry (POE) for HIV consent for alert and oriented patients.
  - C. General consent for comatose/general anesthesia patients will suffice but needs to be documented on Lab Requisition (form MM 68693).
  - D. Refusals should be documented on Lab Requisition (form MM 68693). Notify UTMB Legal 24 hours/day. The Legal Department will make the decision on how source blood will be obtained. (Contact Legal by calling the hospital operator).
  - E. Complete Lab Requisition (form MM 68693).
    - Employees who are off campus can contact employee health and they will fax a completed lab slip to put in the bag with the specimens.
  - F. Assure consent status is documented on form.
  - G. Obtain one (1) serum separator tube.
  - H. Label tube
  - I. Document exposure in source's medical record & that labs were drawn for "source of occupational exposure".
  - J. Send blood to Laboratory Medicine, Sample Management, Rm. 5.136, McCullough Building.
  - K. Laboratory results for personnel/students will be sent to Employee Health/Student Health for follow-up. Source laboratory results will be placed in the source's medical record when consent is granted, or when general consent is invoked. If source refuses testing, results will be sent to Employee Health/Student Health.

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>	<b>01.02 - Policy</b>  <b>08.31.15 - Revised</b> <b>1997 - Author</b>
<b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	

#### IV. EMPLOYEE/STUDENT POST EXPOSURE CARE

- A. Monday through Friday 7:30 AM to 4:30 PM go immediately to the Employee Health Center. Students are seen in Student Health 8AM to 5PM.
- B. Holidays, weekends, or after hours – Go to the Emergency Department immediately.
  1. Triage to ensure initiation of prophylaxis within 2 hours of exposure (percutaneous injury or contamination of mucous membranes or nonintact skin with blood, body fluids visibly contaminated with blood, unfixed tissue, semen, vaginal secretions, and cerebrospinal, synovial, pleural, peritoneal, pericardial, and amniotic fluids).
  2. Obtain consent for HIV test through Physician Order Entry (POE).
  3. Submit Employee/Student specimens using form MM 68693 – two serum separator tubes labeled appropriately.
    - a. Order labs for exposed individual (HIV-1/HIV-2 antibody, HCV antibody and total anti-HBc). In addition, HBV surface antibody should be ordered for employees/students who have a history of HBV immunization prior to coming to UTMB.
    - b. Additional laboratory tests required if Employee/Student is starting prophylaxis for HIV exposure/possible exposure – CBC (use additional lavender top tube for CBC), ALT, AST, total bilirubin, GGT, creatinine, BUN, blood glucose and CPK. Females must have a urine or serum pregnancy test.
    - c. Assure consent for testing is documented.
    - d. Send specimens to Sample Management, Room 5.136 McCullough.
  4. Post-exposure Prophylaxis for Tetanus/Diphtheria, Hepatitis B and Hepatitis C
    - a. Offer tetanus/diphtheria booster following percutaneous injury if none within last 10 years. Offer Tdap vaccine for the booster.
    - b. For vaccinated HCW (who have written documentation of a complete, ≥ 3-dose of Hepatitis B vaccine series) with subsequent ≥ 10 mIU/mL, testing the source patient for HBsAg is unnecessary.

#### **Exposed HCW/Student has never received Hepatitis B vaccine**

- c. Offer HBV vaccine if source is known to be positive for hepatitis B or is high risk for hepatitis B or source is unknown, (e.g., needle puncture through a trash bag) and employee/student has not been vaccinated against hepatitis B.
- d. Offer Hepatitis B Immune Globulin 0.06 ml/kg IM if source is known to be positive for hepatitis B, or is high risk for hepatitis B or source is unknown, (e.g. needle puncture through a trash bag) and employee/student has not been vaccinated against hepatitis B.

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>	<b>01.02 - Policy</b>
<b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	<b>08.31.15 - Revised</b> <b>1997 - Author</b>

**Exposed HCW/Student has received 3 doses of Hepatitis B vaccine twice and anti-HBs < 10 mIU/mL**

- e. For vaccinated HCW/Student (who have written documentation of Hepatitis B vaccination) with anti-HBs < 10 mIU/mL after two complete ≥ 3-dose Hepatitis B vaccine series, the source patient should be tested for HBsAg as soon as possible after the exposure. If the source patient is HBsAg-positive or has unknown HbsAg status, HCW/Student should receive 2 doses of HBIG. The first dose should be administered as soon as possible after exposure and the second dose should be administered 1 month later. If the source patient is HBsAg-negative neither HBIG nor Hepatitis B vaccine is necessary.

**Exposed HCW/Student has received 3 doses of Hepatitis B vaccine but has not been tested for anti-HBs**

- f. For vaccinated HCW/Student (who have written documentation of a complete, ≥ 3-dose Hepatitis B vaccine series) without previous anti-HBs testing, the HCW/Student should be tested for anti-HBs and the source patient (if known) should be tested for HBsAg as soon as possible after the exposure. Testing the source patient and the HCW/Student should occur simultaneously; testing the source patient should not be delayed while waiting for the HCW/Student anti-HBs test results, and likewise, testing the HCW/Student should not be delayed while waiting for the source patient HBsAg results.

**Exposed HCW/Student has < 10 mIU/mL anti-HBs and source patient positive or has unknown HBsAg status**

- g. If the HCW/Student has anti-HBs < 10 mIU/mL and the source patient is HBsAg- positive or has unknown HBsAg status, the HCW/Student should receive 1 dose of HBIG and be revaccinated as soon as possible after the exposure. The HCW/Student should then receive the second 2 doses to complete the second Hepatitis B vaccine series (6 doses total when accounting for the original 3-dose series) according to the vaccination schedule. To document the HCW's/Student's vaccine response status for future exposures, anti-HBs testing should be performed 1-2 months after the last dose of vaccine.

**Exposed HCW/Student has anti-HBs < 10 mIU/mL and the source patient is HBsAg negative**

- h. If the HCW/Student has anti-HBs < 10 mIU/mL and the source patient is HBsAg-negative, the HCW/Student should receive an additional Hepatitis



<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>	<b>01.02 - Policy</b>  <b>08.31.15 - Revised</b> <b>1997 - Author</b>
<b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	

B vaccine dose, followed by repeat anti-HBs testing 1-2 months later. HCWs/Students whose anti-HBs remains < 10 mIU/mL should undergo revaccination with 2 more doses (6 doses total when accounting for the original 3-dose series). To document the HCW's/Student's vaccine response status for future exposures, anti-HBs testing should be performed 1-2 months after the last dose of vaccine.

**Exposed HCW/Student has anti-HBs  $\geq$  10 mIU/mL at time of exposure**

- i. If the HCW/Student has anti-HBs  $\geq$  10 mIU/mL at the time of exposure, no postexposure HBV management is necessary, regardless of the source patient's HBsAg status.

**Exposed HCW/Student unvaccinated or incompletely vaccinated (including those who refused vaccination)**

- j. For unvaccinated or incompletely vaccinated HCW/Student (including those who refused vaccination), the source patient should be tested for HBsAg as soon as possible after the exposure. Testing unvaccinated or incompletely vaccinated HCW/Student for anti-HBs is not necessary and is potentially misleading, because anti-HBs  $\geq$  10 mIU/mL as a correlate of vaccine-induced protection has only been determined for persons who have completed an approved vaccination series.
- k. If the source patient is HBsAg-positive or has unknown HBsAg status, the HCW/Student should receive one dose of HBIG and one dose of Hepatitis B vaccine administered as soon as possible after the exposure. The HCW/Student should complete the Hepatitis B vaccine series according to the vaccination schedule. To document the HCW's/Student's vaccine response status for future exposures, anti-HBs testing should be performed approximately 1-2 months after the last dose of vaccine. Because anti-HBs testing of HCW/Student who received HBIG should be performed after anti-HBs from HBIG is no longer detectable (6 months after administration), it will likely be necessary to defer anti-HBs testing for a period longer than 1-2 months after the last vaccine dose.
- l. Employees/Students testing positive for Hepatitis C Qualitative RNA (PCR) at 6 weeks, 3 months or 6 months, will be referred immediately to a hepatologist for treatment.
- m. Recommend HIV prophylaxis following percutaneous injury or contamination of mucous membranes or nonintact skin with blood, body fluids visibly contaminated with blood, unfixed tissue, semen, vaginal secretions, and cerebrospinal, synovial, pleural, peritoneal, pericardial, and amniotic fluids (**goal is to begin prophylaxis within 2 hours of exposure**).
- n. Prophylaxis medications – write “**UTMB Occupational Exposure**” on prescription

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>	<b>01.02 - Policy</b>
<b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	<b>08.31.15 - Revised</b> <b>1997 - Author</b>

- 1) Dolutegravir 50 mg tablet (Tivicay) One tablet by mouth with or without food once daily for 4 weeks.
- 2) Emtricitabine/tenofovir 200mg/300mg tablet (Truvada), One tablet by mouth with or without food once daily for 4 weeks.
- 3) If the employee/student is on sucralfate, buffered medications (e.g., buffered aspirin), calcium, magnesium, or iron supplements, dolutegravir should be taken 2 hours before or 6 hours after any of these agents. Close monitoring is recommended when starting or stopping dolutegravir and metformin together. A dose adjustment of metformin may be necessary. If the employee/student is on dofetilide, **do not give** dolutegravir. If dolutegravir cannot be given, prescribe the regimen in o. below. This regimen will also be effective prophylaxis for persons who are not pregnant.
  - 4) Provide with 72-96 hour supply of medication.
  - 5) Assure Consent for Post-Exposure Prophylaxis is completed.
- o. Employee/Student is Pregnant – For pregnant women, prophylaxis should be reserved for those with HIGH RISK exposures, and tenofovir (Viread) should not be used. In this case, an alternate regimen should be used:
  - 1) Lopinavir/ritonavir 200/50mg tablet (Kaletra) Two tablets by mouth with or without food every 12 hours for 4 weeks.\*
  - 2) Zidovudine/lamivudine 300mg/150mg tablet (Combivir) One tablet by mouth with or without food every 12 hours for 4 weeks.
  - 3) Provide with 72 – 96 hour supply of medication.
  - 4) Assure Consent for Post-Exposure Prophylaxis is completed.
  - 5) Pregnant employees/students will be followed up by Employee Health/Student Health and will be referred to the Maternal/Child Clinic (409)772-2798.

\*See Appendix A for prescription and over-the-counter drugs that should not be administered with protease inhibitors.



<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>	<b>01.02 - Policy</b>
<b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	<b>08.31.15 - Revised</b> <b>1997 - Author</b>

5. School of Medicine students in the Houston and Austin based programs should follow the prearranged protocol with the specific facilities for evaluation.

F. If the student's insurance is billed for an occupational exposure as in scenario E2, and a bill is received for the balance after insurance coverage, the student should contact Student Health at 409-747-9508 immediately after receiving the bill.

VI. **Any employee claiming a work-related exposure to HIV infection must provide the employer with the BBP Notification Form and document that within 10 days after the date of the exposure, the employee had a test result indicating absence of HIV, HBV, or HCV infection. (Texas Vernon's Civil Statute, Health & Safety Code Section 85.116 (c) for the purpose of qualifying for workers' compensation or any other similar benefits or compensation.**

After hours, weekends, and holidays – call the Access Center (1-800-917-8906).

Employees/students with off campus exposure shall notify Employee Health/Student Health as soon as possible even when treatment was initiated elsewhere.

References:

1. Kuhar DT, Henderson DK, Struble KA, Heneine W, et al. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. *Infect Control Hosp Epidemiol* 2013;34:875-892.
2. Centers for Disease Control and Prevention. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management, 2013;62(No. RR-10):1-16.
3. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med* 2001; 345:1452-7.
4. Tivicay package insert. Research Triangle Park, NC: GlaxoSmithKline; 2013 Aug.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. **Accessed January 29, 2008.**

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>  <b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	<b>01.02 - Policy</b>  <b>08.31.15 - Revised</b> <b>1997 - Author</b>
---	--

## NOTIFICATION FORM

Person completing form \_\_\_\_\_ Signature \_\_\_\_\_ Date/Time \_\_\_\_\_

Name \_\_\_\_\_  Employee  Student

Dept/School \_\_\_\_\_

Supervisor/Faculty \_\_\_\_\_

Home # \_\_\_\_\_ Work # \_\_\_\_\_ Pager # \_\_\_\_\_

Employee# or Student SSN \_\_\_\_\_ Date of Exposure \_\_\_\_/\_\_\_\_/\_\_\_\_ Time \_\_\_\_am\_ pm \_

Location where exposure occurred (*Building, Floor, Rm*) \_\_\_\_\_

Personal Protective Equipment Used: Gloves Goggles/Mask/Faceshield Gown Other

Was a safety device being used? Yes No If so, did it work? Yes No

Type & Brand of safety device \_\_\_\_\_

Body part exposed (*circle one*) hand, eye, mouth, other (*please identify*) \_\_\_\_\_

Describe how exposure occurred. \_\_\_\_\_

Type of body substance exposed to: blood body fluid contaminated by blood semen,  
vaginal secretions and cerebrospinal, synovial, pleural, peritoneal,  
pericardial and amniotic fluids and unfixed human tissue

Type of exposure: needlestick.....Depth of injury \_\_\_\_\_

(check all that apply) cut.....Depth of injury \_\_\_\_\_

Fluid injected Yes No – Estimated volume: \_\_\_\_\_

Mucous membranes

Non-intact skin (e.g., chapped, abraded, or otherwise non-intact)

Did this exposure occur during the employee's/student's normal work activities? Yes No

Is patient source known? Yes No Was source consent obtained? Yes No

Source lab testing done? Yes No Source on antiretroviral therapy? Yes No

List Drugs \_\_\_\_\_

Was source blood sent to lab? Yes No

Source name \_\_\_\_\_ UH# \_\_\_\_\_ Location \_\_\_\_\_

Exposed employee/student lab testing done? Yes No

(For Females)- Pregnancy test result \_\_\_\_\_

Was prophylaxis initiated? Yes No Date/Time of 1st dose \_\_\_\_/\_\_\_\_/\_\_\_\_ Time \_\_\_\_am\_ pm \_

Have you had training on Standard Precautions within the last 12 months? Yes No

### FAX THIS FORM TO:

**(409) 747-9182-Employees**

**(409) 747-9330-Students**

### For questions call:

**Mon-Fri 7:30am-4:30 pm**

**Mon-Fri 8:00am-5:00pm**

**(409) 747-9172-Employees**

**(409) 747-9508-Students**

**Access Center 1-800-917-8906**

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>  <b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	<b>01.02 - Policy</b>  <b>08.31.15 - Revised</b> <b>1997 - Author</b>
---	--

## BLOOD BORNE PATHOGENS EXPOSURE MANAGEMENT FORM <sup>\*</sup>

University of Texas Medical Branch – Employee Health/Student Health

Name \_\_\_\_\_  
(Last) (First) (MI)

Employee  Student    Employee Dept. \_\_\_\_\_ Position \_\_\_\_\_

Phone: \_\_\_\_\_  
(Home) (Pager) (Work)

Date of Exposure \_\_\_\_\_ Time of Exposure \_\_\_\_\_ am/pm

Initial Care of Injury/Exposure

Site \_\_\_\_\_

Date of Evaluation (Initial) \_\_\_\_\_ Time of Evaluation (Initial) \_\_\_\_\_ am/pm

Completed BBP Notification Form attached.

**SOURCE INFORMATION AT TIME OF INCIDENT**       Known Source     Unknown Source

Name \_\_\_\_\_ UH# \_\_\_\_\_

Account # \_\_\_\_\_ Location \_\_\_\_\_

### SOURCE LAB RESULTS

	Date Drawn	Results
HIV		
HBsAg (Hep B surface antigen)		
HCV		

### HEPATITIS AND TETANUS

Hepatitis B Vaccine	[ 0 ] [ 1 ] [ 2 ] [ 3 ]
Date Last Dose:	_____
Antibody Response:	<input type="checkbox"/> anti-HBs ≥10 mIU/mL <input type="checkbox"/> anti-HBs <10 mIU/mL <input type="checkbox"/> Unknown
Hepatitis B Vaccine Given:	<input type="checkbox"/> Yes <input type="checkbox"/> No    Date Given: _____
Immunoprophylaxis: HBIG	<input type="checkbox"/> Yes <input type="checkbox"/> No    Date Given: _____
Tetanus/Diphtheria Booster (Tdap <sup>†</sup> ):	Date of Last Dose: _____
Booster Given:	<input type="checkbox"/> Yes <input type="checkbox"/> No    Date Given: _____

\* See Appendix B for flow diagram on exposure management.

† If patient refuses Tdap, offer Td.



**Section: UTMB On-line Documentation**  
**Subject: Healthcare Epidemiology Policies and Procedures**

**01.02 - Policy**

**Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis**

**08.31.15 - Revised**  
**1997 - Author**

**CHECK FOLLOW-UP NEEDED:**

- 2 Weeks** (If on prophylaxis)
- 4 Weeks** (If on prophylaxis)
- 6 Weeks** (HIV+source. HCV+source)
- 3 Months** (HIV+source. HCV+source. Unknown source)
- 6 Months** (HIV+source. HCV+source. Unknown source).
- 12 Months** (HIV+source)

**FOLLOW-UP DIRECTIONS:**

HIV+source = HIV drawn  
HCV+source = **HCV Qual-RNA (PCR)** drawn  
HIV/HCV (-) = HIV drawn  
Unknown source = HIV and HCV drawn

**2 WEEK FOLLOW-UP \_\_/\_\_/\_\_ RESULTS**

If placed on prophylaxis:

CBC	
Total bilirubin, ALT, AST, GGT	
Pregnancy Test (urine or serum)	
Creatinine, BUN	
Blood glucose	
CPK	

Results  
Reported \_\_/\_\_/\_\_ Via \_\_\_\_ By \_\_\_\_\_

**4 WEEK FOLLOW-UP \_\_/\_\_/\_\_ RESULTS**

If placed on prophylaxis:

CBC	
Total bilirubin, ALT, AST, GGT	
Creatinine, BUN	
Blood glucose	
CPK	

Results  
Reported \_\_/\_\_/\_\_ Via \_\_\_\_ By \_\_\_\_\_

**6 WEEK FOLLOW-UP \_\_/\_\_/\_\_ RESULTS**

HIV, CBC	
Total bilirubin, ALT, AST, GGT	
Creatinine, BUN, blood glucose	
HCV Qual RNA (PCR) (only if source blood Hep C+)	
CPK	

Results  
Reported \_\_/\_\_/\_\_ Via \_\_\_\_ By \_\_\_\_\_

**3 MONTH FOLLOW-UP \_\_/\_\_/\_\_ RESULTS**

HIV	
HCV Qual RNA (PCR) (only if source blood Hep C+)	

Results  
Reported \_\_/\_\_/\_\_ Via \_\_\_\_ By \_\_\_\_\_

**6 MONTH FOLLOW-UP \_\_/\_\_/\_\_ RESULTS**

HIV	
HCV Qual RNA (PCR) (only if source blood Hep C+)	
HBsAg	
Total anti-HBc	

Results  
Reported \_\_/\_\_/\_\_ Via \_\_\_\_ By \_\_\_\_\_

**12 MONTH FOLLOW UP \_\_/\_\_/\_\_ RESULTS**

HIV	
-----	--

Results  
Reported \_\_/\_\_/\_\_ Via \_\_\_\_ By \_\_\_\_\_



<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>  <b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	<b>01.02 - Policy</b>  <b>08.31.15 - Revised</b> <b>1997 - Author</b>
---	--

**ASSESSMENT/RECOMMENDATIONS:**

Warnings discussed to avoid pregnancy and/or breast feeding during treatment (females)  Yes  No  
Employee Assistance Program/Counseling  Referral Made  Declined  
Post-Exposure Treatment:  Recommended  Not Recommended  
Informed Consent:  Obtained  Refused  
Post-Exposure Prophylaxis:  Declined  Provided  
Date/Time of 1st dose \_\_\_\_/\_\_\_\_/\_\_\_\_-\_\_\_\_\_AM/PM  
Printed Materials Provided:  Yes  No

Comments: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Nurse : \_\_\_\_\_ Date: \_\_\_\_\_

Healthcare Provider: \_\_\_\_\_ Date: \_\_\_\_\_

Provider Information: Name: \_\_\_\_\_  
Clinic: \_\_\_\_\_  
Address: \_\_\_\_\_  
Phone: \_\_\_\_\_

After follow-up is completed, provider is to forward to:	<u>for employees</u> Employee Health Primary Care Pavilion 400 Harborside Drive Route 1161 FAX (409) 747-9182	<u>for students</u> Student Health Rebecca Sealy Hospital 301 University Boulevard Route 0169 FAX (409) 747-9330
---	--	---

For questions call: Employees (409) 747-9172 Students (409) 747-9508  
Access Center (800) 917-8906

**Situations for which Infectious Diseases Consultation for Human Immunodeficiency Virus (HIV) postexposure prophylaxis (PEP) is recommended. *Provision of PEP should not be delayed while awaiting expert consultation.***

- Delayed (ie, later than 72 hours) exposure report. Interval after which benefits from PEP are undefined.
- Breastfeeding in the exposed person
- If source person’s virus is known or suspected to be resistant to one or more of the drugs considered for PEP, selection of drugs to which the source person’s virus is unlikely to be resistant is recommended.
- Toxicity of the initial PEP regimen
  - Symptoms (eg, gastrointestinal symptoms and others) are often manageable without changing the PEP regimen by prescribing antimotility or antiemetic agents.
- Serious medical illness in the exposed person who is already taking multiple medications may increase the risk of drug toxicity and drug-drug interactions.

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>	<b>01.02 - Policy</b>  <b>08.31.15 - Revised</b> <b>1997 - Author</b>
<b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	

## Occupational Exposures to Blood Borne Pathogens Patient (Employee/Student) Information

### Risk of HIV Infection

The average risk of HIV infection due to all types of reported percutaneous exposures to HIV-infected blood is 0.3%. A percutaneous exposure is defined as a needlestick or laceration/puncture with a sharp object.

The risk appears to be greater than 0.3% for exposure to HIV (+) patients involving deep injury, visible blood on the device causing the injury or a device previously placed in the source patient's vein or artery.

### Risk of Hepatitis B or Hepatitis C Infection

The average risk of Hepatitis B virus (HBV) infection in susceptible persons after percutaneous exposure to HBV-infected blood is 6 – 30%. The risk of Hepatitis C virus (HCV) infection after percutaneous exposure to HCV-infected blood is 7.4% (95% CI 3.9%-12.5%).

### Prophylaxis for Exposure to HIV (Revised September, 2013)

Prophylaxis is being offered to employees and students who have a percutaneous injury or contamination of mucous membranes or nonintact skin exposure to HIV during the performance of their duties. Prophylaxis in these circumstances is voluntary. The FDA has not approved antiretroviral therapy for post-exposure use; therefore, use of these medications post-exposure for healthcare workers/students is considered investigational. The CDC says, "Because most occupational exposures to HIV do not result in infection transmission, potential toxicity must be carefully considered when prescribing post-exposure prophylaxis (PEP)".

### Medication Schedule

#### Regimen 1

**Prophylaxis will be treatment for four weeks with:**

**Dolutegravir 50 mg tablet (Tivicay) One tablet by mouth with or without food once daily for 4 weeks.**

**AND**

**Emtricitabine/Tenofovir 200mg/300mg tablet (Truvada) One tablet by mouth with or without food once daily for 4 weeks.**

Side effects associated with dolutegravir (Tivicay) include nausea, diarrhea, headache, dizziness, abnormal dreams and difficulty sleeping.

Side effects associated with emtricitabine/tenofovir (Truvada) include nausea, vomiting, diarrhea, abdominal pain, dizziness, gas, loss of appetite, headache, rash, skin discoloration, joint pain and muscle pain. Rarely, this medication may cause jaundice with dark urine and yellowing of the skin or eyes.

**Regimen 2 (see below) is to be used instead of Regimen 1 during pregnancy or if pregnancy is possible, or if there is intolerance to components of Regimen 1 or if there could be a possible drug interaction between the medications in regimen 1 and medications the employee/student is already taking.**

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>	<b>01.02 - Policy</b>  <b>08.31.15 - Revised</b> <b>1997 - Author</b>
<b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	

**Regimen 2**

**Prophylaxis will be treatment for four weeks with:**

**Lopinavir/ritonavir 200/50mg tablet (Kaletra) Two tablets by mouth with or without food every 12 hours for 4 weeks.**

**AND**

**Zidovudine/lamivudine 300mg/150mg tablet (Combivir) One tablet by mouth with or without food every 12 hours for 4 weeks.**

Side effects associated with lopinavir/ritonavir (Kaletra) include nausea, vomiting, diarrhea, weakness, hyperlipidemia, elevated serum transaminases, hyperglycemia, and fat maldistribution.

Side effects associated with zidovudine include headache, nausea, muscle aches and pains, fatigue, and trouble sleeping. These side effects are expected to stop when zidovudine is discontinued.

Severe anemia (low red blood cells), neutropenia (low white blood cells), and liver cell damage are serious side effects that may develop in individuals taking zidovudine.

Side effects associated with lamivudine are uncommon and include nausea, diarrhea, abdominal pain, muscle pain, headache, dizziness, and difficulty sleeping. Any history of pre-existing renal impairment should be noted, and the dose should be reduced if renal insufficiency (creatinine clearance < 50 ml/min) is present.

The risk of long-term toxicities, for example, birth defects, reproductive capacity, development of tumors, or other long-term effects of these medications are unknown.

**Pregnancy**

The risks of adverse effects to a developing fetus from antiretroviral therapy taken by a pregnant woman are unknown, but the risks are likely to be greater in the first trimester. Therefore, females taking antiretroviral therapy post-exposure should be aware that there may be risks associated with antiretroviral therapy during pregnancy, and prophylaxis should be reserved for those with HIGH RISK exposures. If a female is found to be HIV ELISA positive or to have a low value on viral load test, they should be referred to the HIV Maternal Fetal Child Health Clinic (409) 772-2798.

**Routine Occupational Exposure Follow-up**

Follow-up is determined by the results of the initial lab work drawn on the source of the occupational exposure. It proceeds as follows:

<b><u>Known HIV(+)</u> source</b>	Obtain HIV antibody @ exposure
	6 weeks
	3 months
	6 months
	12 months

<b><u>Known HBV (+)</u> source</b>	Obtain Total anti-HBc @ exposure
Obtain HBsAg and Total anti-HBc	6 months

<b><u>Known HCV(+)</u> source</b>	Obtain HCV antibody @ exposure
Obtain HCV Qual RNA (PCR)	6 weeks
	3 months
	6 months

<b>Section: UTMB On-line Documentation</b> <b>Subject: Healthcare Epidemiology Policies and Procedures</b>  <b>Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis</b>	<b>01.02 - Policy</b>  <b>08.31.15 - Revised</b> <b>1997 - Author</b>
---	--

Unknown source

Obtain HIV & HCV antibody @ exposure  
3 months  
6 months  
Obtain Total anit-HBc @ exposure and  
HBsAg and Total anti-HBc  
6 months

If the source results are HIV (-) and HCV (-), you will be offered a one-time 6-month follow-up at which time only an HIV will be drawn.

Special Precautions after an HIV(+) or High Risk Exposure

- ◆ Do not share a toothbrush. Gums can bleed easily, getting blood on the toothbrush.
- ◆ Do not share razors as blood may go undetected on the blade.
- ◆ Avoid pregnancy until HIV infection is ruled out (i.e. generally 6 months following exposure, but up to one year).
- ◆ Use safe sex practices-male/female latex condoms for barrier protection or abstain from sex during the follow-up period until HIV infection has been ruled out.
- ◆ Do not donate blood, plasma, organs, tissue or semen during the follow-up period.
- ◆ Seek medical evaluation for any acute illness that occurs during the follow-up period.

## INFORMED CONSENT FOR PROPHYLAXIS AFTER BLOOD BORNE PATHOGENS EXPOSURE

As a patient, you have the right to be informed about your risk after a blood borne pathogens (BBP) exposure and the recommended prophylaxis. This disclosure is not meant to alarm you; however, there are certain side effects which are associated with prophylaxis. I have read and understand the patient information entitled "Occupational Exposures to Blood Borne Pathogens- Patient Information," which explains risks of infection, prophylaxis, medication schedule, pregnancy precautions, follow-up and special precautions.

- I hereby voluntarily consent to prophylaxis for exposure to blood and body fluids infected or possibly infected with human immunodeficiency virus-1(HIV-1). The medications include:

---

---

---

---

---

---

---

---

- I hereby decline prophylaxis following my exposure to blood borne pathogens. The healthcare provider has informed me of the possible risks associated with refusing this medication. The nature and purpose of the proposed prophylaxis & the risks and hazards if the treatment is withheld, have been explained to me by a healthcare provider. I have had an opportunity to discuss these matters with a healthcare provider and to ask questions about my exposure, alternatives, and the proposed treatment.

---

EMPLOYEE Date Time

---

HEALTHCARE PROVIDER Date Time

---

WITNESS Date Time

\*\*\*\*\* Please forward to Employee Health/Student Health \*\*\*\*\*

Section: UTMB On-line Documentation  
Subject: Healthcare Epidemiology Policies and Procedures

01.02 - Policy

Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure  
Prophylaxis

08.31.15 - Revised  
1997 - Author

## Prescription for All Employees/Students Who are not Pregnant

The University of Texas Medical Branch Hospitals 301 University Boulevard • Galveston, Texas 77555-0701 (409) 772-1011	
_____ (Pt. Name)	
_____ (Address)	
AGE: _____	WT: _____
DATE: _____	ALLERGIES: _____

A generically equivalent drug product will be dispensed unless the practitioner hand writes the words  
"Brand Necessary" or "Brand Medically Necessary" on the face of the prescription.

**R**

SIG: 1. *Dolutegravir 50 mg*  
a. *One tablet p.o. Q day x \_\_\_ days supply*

2. *Truvada*  
a. *One tablet p.o. Q day x \_\_\_ days supply*

Dispense:  
6 months   
3 months   
1 month

Quantity # \_\_\_\_\_

**(CONTROLLED SUBSTANCES REQUIRE QUANTITY NUMBER AND WRITTEN WORD.)**

DO NOT REFILL

REFILL  1  2  3  4  5

INDICATION: \_\_\_\_\_

\_\_\_\_\_  
PRINTED NAME

\_\_\_\_\_  
M.D. SIGNATURE

DEA No. AG3353973- \_\_\_\_\_ or DEA No. \_\_\_\_\_  
Telephone/  
Pager \_\_\_\_\_

MM68706-Rev. 5/02

### Emergency Department Instructions:

Sun – Thurs ... prescribe 2 days of medication

Fri – Sat ... prescribe 3 days of medication

(Allow for additional days if a Holiday falls in this time period)

Section: UTMB On-line Documentation  
Subject: Healthcare Epidemiology Policies and Procedures

01.02 - Policy

Topic: 01.02 – Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis

08.31.15 - Revised  
1997 - Author

## Prescription for Pregnant Employees/Students

The University of Texas Medical Branch Hospitals 301 University Boulevard • Galveston, Texas 77555-0701 (409) 772-1011	
_____ (Pl. Name)	
_____ (Address)	
AGE: _____	WT: _____
DATE: _____	ALLERGIES: _____

A generically equivalent drug product will be dispensed unless the practitioner hand writes the words "Brand Necessary" or "Brand Medically Necessary" on the face of the prescription.

**R**

1. *Kaletra (Lopinavir/Ritonavir 200/50mg)*  
SIG: a. *Two tablets p.o. Q 12 hours x \_\_\_ days supply*

2. *Combivir*  
a. *One tablet p.o. Q 12 hours x \_\_\_ days supply*

Dispense:  
6 months   
3 months   
1 month

Quantity # \_\_\_\_\_

**(CONTROLLED SUBSTANCES REQUIRE QUANTITY NUMBER AND WRITTEN WORD.)**

DO NOT REFILL

REFILL  1  2  3  4  5

INDICATION: \_\_\_\_\_

\_\_\_\_\_  
PRINTED NAME M.D. \_\_\_\_\_  
M.D. SIGNATURE M.D.

DEA No. AG3353973- \_\_\_\_\_ or DEA No. \_\_\_\_\_  
Telephone/  
Pager \_\_\_\_\_

MM68706-Rev. 5/02

### Emergency Department Instructions:

Sun – Thurs ... prescribe 2 days of medication

Fri – Sat ... prescribe 3 days of medication

(Allow for additional days if a Holiday falls in this time period)

<b>Section:</b> UTMB On-line Documentation	<b>1.2 - Policy</b>
<b>Subject:</b> Healthcare Epidemiology Policies and Procedures	
<b>Topic:</b> 01.02 - Blood Borne Pathogens (BBP) Occupational Post-Exposure Prophylaxis	<b>7.25.14 - Revised 1997 - Author</b>

## Appendix A. Prescription and over-the-counter drugs that should not be administered with protease inhibitors (PIs) because of drug interactions.

Drug	Comment
Antimycobacterials: rifampin	Decreases plasma concentrations and area under plasma concentration curve of the majority of PIs by approximately 90%, which might result in loss of therapeutic effect and development of resistance
Benzodiazepines: midazolam, triazolam	Contraindicated because of potential for serious or life-threatening events (e.g., prolonged or increased sedation or respiratory depression)
Ergot derivatives: dihydroergotamine, ergotamine, ergonovine, methylegonovine	Contraindicated because of potential for serious or life-threatening events (e.g., acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues)
Gastrointestinal motility agent: cisapride	Contraindicated because of potential for serious or life-threatening events (e.g., cardiac arrhythmias)
HMG-CoA reductase inhibitors ("statins"): lovastatin, simvastatin	Potential for serious reactions (e.g., myopathy, including rhabdomyolysis); atorvastatin may be used cautiously, beginning with lowest possible starting dose, and monitoring for adverse events
Neuroleptic: pimozide	Contraindicated because of potential for serious or life-threatening events (e.g., cardiac arrhythmias)
Inhaled steroids: fluticasone	Coadministration of fluticasone and ritonavir-boosted protease inhibitors are not recommended unless the potential benefit to the patient outweighs the risk for systemic corticosteroid side effect
Herbal products: St. John's wort (hypericum perforatum), garlic	Coadministration might reduce plasma concentrations of protease inhibitors, which might result in loss of therapeutic effect and development of resistance Garlic might lower saquinavir level

This table does not list all products that should not be administered with PIs (atazanavir, lopinavir/ritonavir, fosamprenavir, indinavir, nelfinavir, saquinavir).


Product labels should be consulted for additional information regarding drug interactions.

Sources: US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: US Department of Health and Human Services; 2005. Available at [http://www.aidsinfo.nih.gov/guidelines/adult/AA\\_040705.pdf](http://www.aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf); University of California at San Francisco Center for HIV Information. Database of antiretroviral drug interactions. Available at <http://hivinsite.ucsf.edu/InSite?page=ar-00-02>.




## Appendix B. OCCUPATIONAL EXPOSURES TO BLOOD BORNE PATHOGENS (BBP)\*

### Supervisor/Employee/Student Actions



### Treatment Provider (Employee Health/Student Health/ED†) or Off-site Provider



\* Off-site clinics refer to your agency specific policy  
 † Emergency Department  
 ‡ See n. 3) on page 9 for drug interactions with dolutegravir

\*After-hours questions, call  
 Access Center @ 1-800-917-8906